Suven Life Sciences Overview
- Founded
-
1989
- Status
-
Public
- Employees
-
117
- Stock Symbol
-
530239
- Investments
-
1
- Share Price
-
$0.59
- (As of Friday Closing)
Suven Life Sciences General Information
Description
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company's geographical segment includes India; the USA; Europe and Others. It generates maximum revenue from the USA. The company's only segment being providing Research and Development services. The company earns revenue primarily from the sale of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API) Speciality chemicals, and formulated drugs under contract research and manufacturing services.
Contact Information
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Primary Office
- 6th Floor, SDE Serene Chambers
- Avenue-7, Road No. 5, Banjara Hills
- Hyderabad, Telangana 500034
- India
+91 040 0000 0000
Suven Life Sciences Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.59 | $0.58 | $0.55 - $1.24 | $126M | 218M | 24.7K | -$0.09 |
Suven Life Sciences Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 179,079 | 175,521 | 121,638 | 31,604 |
| Revenue | 1,928 | 1,590 | 1,812 | 2,029 |
| EBITDA | (13,520) | (15,864) | (10,657) | (16,180) |
| Net Income | (14,180) | (16,374) | (9,698) | (13,261) |
| Total Assets | 14,247 | 17,485 | 24,123 | |
| Total Debt | 0 | 423 | 649 | 797 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Suven Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Suven Life Sciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company's geographical segment includes India;
Pharmaceuticals
Hyderabad, India
117
As of 2022
0000
0000-00-00
000000000000
000000
tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
000000000000000
Noida, India
0000
As of 0000
00000
0000
0000-00-00
00000000000
00000
00. 00
ip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
000000000000000
Hyderabad, India
00000
As of 0000
00000
00000000000
00000
Add Comparison
Suven Life Sciences Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Jubilant Pharmova | Corporation | Noida, India | 0000 | 00000 | 00000000000 | 00000 |
| 00. 00000'0 000000 | Corporation | Hyderabad, India | 00000 | 00000 | 00000000000 | 00000 |
| 000000000 | Corporation | Mumbai, India | 0000 | 000000000 | ||
| 000 00000000000000 | Corporation | Mumbai, India | 00000 | 000000000000 | ||
| 00000 000000000000 | Corporation | Ahmedabad, India | 00000 | 000.00 | 00000000 | 000.00 |
Suven Life Sciences Patents
Suven Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3162938-A1 | Methods for treating behavioral and psychological symptoms in patients with dementia | Pending | 02-Dec-2019 | 0000000000 | |
| EP-4069231-A1 | Methods for treating behavioral and psychological symptoms in patients with dementia | Pending | 02-Dec-2019 | 0000000000 | |
| JP-2023510082-A | Methods for treating behavioral and psychological symptoms in patients with dementia | Pending | 02-Dec-2019 | 0000000000 | |
| US-20230000859-A1 | Methods for treating behavioral and psychological symptoms in patients with dementia | Pending | 02-Dec-2019 | 000000000 | |
| AU-2020398082-A8 | Treating behavioral and psychological symptoms in dementia patients | Pending | 02-Dec-2019 | A61K31/496 |
Suven Life Sciences Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Venkat Jasti | Chief Executive Officer & Chairman |
Suven Life Sciences Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000000 000000 | Suven Life Sciences | Board Member | 000 0000 |
| 0000000000000 0000 | Suven Life Sciences | Board Member | 000 0000 |
| 00000 00000 | Suven Life Sciences | Board Member | 000 0000 |
| 000000 00000 | Suven Life Sciences | Chief Executive Officer & Chairman | 000 0000 |
Suven Life Sciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Suven Life Sciences Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 00000 0 | 07-Mar-2019 | 00000 0000 | Drug Discovery | 000000 00 |
Suven Life Sciences ESG
Risk Overview
Risk Rating
Updated June, 16, 2022
37.33 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 899
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 431
Rank
00.00
Percentile
